OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr Sells 13,964 Shares

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 13,964 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $3.68, for a total value of $51,387.52. Following the completion of the sale, the chief executive officer now owns 3,798,682 shares of the company’s stock, valued at $13,979,149.76. This trade represents a 0.37 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

OmniAb Price Performance

Shares of NASDAQ:OABI traded up $0.01 during trading on Wednesday, hitting $3.67. 294,723 shares of the company’s stock were exchanged, compared to its average volume of 489,354. The business’s 50-day simple moving average is $3.49 and its 200 day simple moving average is $3.91. The company has a market cap of $518.28 million, a price-to-earnings ratio of -5.92 and a beta of -0.12. OmniAb, Inc. has a 52-week low of $3.10 and a 52-week high of $6.55.

Analyst Ratings Changes

Several research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. Benchmark reaffirmed a “buy” rating and set a $8.00 price target on shares of OmniAb in a report on Thursday, November 14th.

Institutional Investors Weigh In On OmniAb

A number of institutional investors have recently added to or reduced their stakes in OABI. SG Americas Securities LLC lifted its holdings in shares of OmniAb by 105.6% in the third quarter. SG Americas Securities LLC now owns 34,858 shares of the company’s stock worth $147,000 after buying an additional 17,901 shares in the last quarter. CWC Advisors LLC. bought a new stake in OmniAb in the 3rd quarter valued at $54,000. China Universal Asset Management Co. Ltd. lifted its stake in OmniAb by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock worth $96,000 after purchasing an additional 8,909 shares in the last quarter. Palumbo Wealth Management LLC boosted its holdings in shares of OmniAb by 12.5% during the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after purchasing an additional 2,744 shares during the last quarter. Finally, Rice Hall James & Associates LLC grew its position in shares of OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock valued at $11,515,000 after purchasing an additional 163,038 shares in the last quarter. 72.08% of the stock is owned by hedge funds and other institutional investors.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.